Locations: 
London
Sheffield

Full title: Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (Invictus)  

Age: 18+              
Phase: 3               

If you have a GIST which can’t be removed with surgery or has come back, you may be treated with chemotherapy. This trial looks at how effective a new drug (DCC 2618/ripretinib) is when a GIST has got worse despite being treated with chemotherapy drugs imatinib, sunitinib and regorafenib. The new drug is compared with a placebo which is given in the same way but does not contain any drug or medicine. Therefore not everyone who takes part in this trial will be given the new drug, some will be given a placebo.

Ripretinib is now also available via a Global Expanded Access Program, which allows eligible patients to receive it outside of a trial setting.

Patients with advanced unresectable or metastatic GIST who have a KIT or PDGRFα mutation, do not meet the criteria for ongoing clinical studies, and have received two or more prior treatments may be eligible.

You will need your doctor to make a formal request via email to managedaccess@clinigengroup.com. They should receive a notification of receipt within one working day and will receive more details about the guidelines around participation.